Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Policy topic
No spam. Unsubscribe anytime.
Senators hear emotional testimony on expanding coverage for newly approved Alzheimer’s therapies; no committee vote due to lack of quorum
Summary
Lawmakers heard patients and advocates support House Bill 1055, which would require state employee and school employee plans to cover FDA‑approved Alzheimer’s treatments; state benefits officials and clinical reviewers raised safety, evidence and fiscal concerns and the committee did not vote because of a lost quorum.
Representative Julie Mayberry and the Alzheimer’s Association presented House Bill 1055 to the committee to require coverage of Food and Drug Administration‑approved treatments for Alzheimer's disease under state employee and public‑school employee health plans.
"Medicaid, Medicare, veterans, they get this medicine. Our state employees and our school employees do not," Mayberry said, urging parity in access. David Koch of the Alzheimer’s Association described the therapies as first‑generation treatments that target amyloid plaque and are intended for patients in early disease stages with confirmed amyloid biology.
Retired teacher Steve Daniels, who described his own diagnosis and treatment experience, told senators the infusion therapy he receives “will extend my life dramatically for years, where I'll still know their names and I'll still know their faces for years to come.” Daniels said the treatment had enabled marked functional improvement in his case.
State benefits officials and clinical reviewers urged caution. Grant Wallace, director of the Employee Benefits Division, told the committee the bill as drafted would shift formulary control, saying language in the draft—"according to the standards of guidance established by the United States Food and Drug Administration"—would require automatic coverage of any FDA‑approved product and "subverts the process" the committee typically uses to review and adopt medications for state plans. Wallace estimated a $2 million to $4 million fiscal impact and said the division had concerns about the bill’s scope.
Trey Gardner of the UAMS Evidence‑Based Prescription Drug Program explained his committee’s clinical review and said the drugs approved to date did not meet minimum clinically important difference in the trials his panel reviewed and carry safety risks. "For Lekimbe, 1 in 9 patients will experience brain swelling. 1 in 10 will experience brain bleeding, cerebral hemorrhage," he said, and said adverse‑event rates for the other FDA‑approved drug were higher.
Committee members debated the tradeoffs: patients and advocates emphasized potential life‑extending and quality‑of‑life benefits, while benefits officials stressed clinical uncertainty, significant side effects and fiscal consequences. Because the committee lacked a quorum at the scheduled time for a vote, senators did not take formal action on HB 1055 at that hearing.
